BioNTech Change In Cash Over Time
| BNTX Stock | USD 113.13 4.90 4.53% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioNTech Performance and BioNTech Correlation. BioNTech |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.227 | Earnings Share (2.04) | Revenue Per Share 12.618 | Quarterly Revenue Growth 0.39 | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare BioNTech SE and related stocks such as Novavax, CohBar Inc, and Ginkgo Bioworks Holdings Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | (2.1 M) | 6 M | 3.3 M | 102.1 M | (87.1 M) | 60.8 M | 51.2 M | (38 M) | (53.5 M) | 221 K | 566.6 M | 879.5 M | (179.4 M) | (765 M) | (726.8 M) |
| DNA | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | 291.1 M | (112.6 M) | 1.2 B | (223.3 M) | (380 M) | (361 M) |
| CRSP | 584 K | 584 K | 584 K | 584 K | 584 K | 155 M | 159.6 M | (75.8 M) | 216.9 M | 489 M | 236.7 M | (245.5 M) | (715.9 M) | 177 M | 185.9 M |
| OCEA | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 64 K | 60 K | (747.3 K) | (672.6 K) | (638.9 K) |
| ENVB | (200 K) | 17.1 K | (16.9 K) | (1.1 K) | 4.8 K | 1.1 M | (498.1 K) | 3.5 M | (3.5 M) | (939.9 K) | 1.5 M | 15.8 M | 367.9 K | (15.4 M) | (14.7 M) |
| HEPA | 520.3 K | 520.3 K | 520.3 K | 1.7 M | 1.7 M | 2.7 M | 2.8 M | 5.6 M | (3.1 M) | 11.1 M | 26.8 M | 50.6 M | (40.2 M) | (36.4 M) | (34.6 M) |
| ELEV | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 77.7 M | 66.9 M | (100.4 M) | 3.3 M | 3.2 M |
| PTCT | (243.5 K) | (243.5 K) | (25.7 M) | 12.7 M | 34.3 M | 8.3 M | 299 K | 53.5 M | 57.7 M | 126 M | (79.2 M) | (19.1 M) | 98.7 M | 314.4 M | 330.1 M |
| KRYS | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 47.7 M | 54.1 M | 83.8 M | 80.8 M | 73 M | (179.3 M) | 196.4 M | 206.2 M |
| SRPT | (1.2 M) | 6.3 M | 147.8 M | 69.3 M | (183.4 M) | 6.8 M | 42.1 M | 477.3 M | (229 M) | 472.8 M | 668.1 M | 613.8 M | (1.1 B) | (541.8 M) | (514.7 M) |
| IOVA | (57.3 K) | (782.3 K) | (510.2 K) | (510.2 K) | 25.2 M | (31.3 M) | 73.1 M | 38.7 M | (63.2 M) | (62.7 M) | 53.4 M | 11.5 M | 153.8 M | (56.8 M) | (54 M) |
| MDGL | 7.1 M | (1.2 M) | 51.4 M | (33 M) | (2.5 M) | (11.1 M) | 18.8 M | 129.5 M | (91.2 M) | (10.7 M) | 7.3 M | (17.7 M) | 295.3 M | (231.6 M) | (220.1 M) |
BioNTech SE and related stocks such as Novavax, CohBar Inc, and Ginkgo Bioworks Holdings Change In Cash description
My Equities
My Current Equities and Potential Positions
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.